ClinicalTrials.gg
CompletedNCT04254783Updated Jul 1, 2024

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

A Phase 1 interventional study of Risankizumab and Cytochrome P450 (CYP) Substrates in Ulcerative Colitis (UC) and Crohn's Disease, sponsored by AbbVie. Completed at 6 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2022, 4 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Colitis, Ulcerative by AbbVie — 6 open to participants now, 13 under way, 5 of them phase 3. Colitis, Ulcerative · AbbVie.

Enrollment
29th of 31
20 · median 156
Started
2020
with 1 other
Phase 1
4 of 53
none open now
Registered
33rd of 53
by date

Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 29th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 1, and was the 33rd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

6 of the 53 studies in Colitis, Ulcerative by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Colitis, Ulcerative by AbbVie, or all of them as a file.
02

Study summary

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever. This study will evaluate the effect of repeated infusions of risankizumab on the pharmacokinetics of sensitive probe substrates of Cytochrome P450 (CYP) enzymes in participants with moderately to severely active UC or CD.

Risankizumab is an investigational drug being developed to treat trial participants with inflammatory diseases such as UC and CD. The study is split into two periods. In Period 1, participants will receive single oral doses of CYP sensitive probes and in Period 2, participants will receive risankizumab followed by single oral doses of CYP sensitive probes. Around 20 adult participants with moderately to severely active CD or UC will be enrolled in the study across multiple sites worldwide.

In Period 1, participants will receive oral doses of CYP sensitive probes on Day 1. In Period 2, participants will receive risankizumab by intravenous (IV) infusion on Days 1, 29 and 57 followed by oral CYP sensitive probes on Day 64.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.

03

Conditions studied

  • Ulcerative Colitis (UC)
  • Crohn's Disease

Keywords

  • Ulcerative Colitis (UC)
  • Crohn's Disease
  • Risankizumab
  • SKYRIZI
  • ABBV-066
  • Cytochrome P450
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of UC or CD for at least 3 months prior to Day -1 (baseline). Appropriate documentation of results consistent with the diagnosis of CD or UC, in the assessment of the gastroenterologist, must be available.
  • Moderately to severely active CD or UC.
  • Must have demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates, oral locally acting , systemic steroids, immunomodulators, and/or approved biologic therapies.
  • Participant must agree to not use any known inhibitors or inducers of cytochrome P450 within 1 month or 5 half-lives, whichever is greater before each administration of the cocktail probe and until the last pharmacokinetic sample is collected, 7 days after the intake of each probe cocktail.

Exclusion criteria

Exclusion Criteria:

  • History of any sensitivity or allergy to any medication or food.
  • History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption (e.g., celiac disease, gastroparesis, cholecystectomy, vagotomy).
  • Positive for COVID-19 infection signs and symptoms.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Cytochrome P450 (CYP) + Risankizumab

    In Period 1, participants will receive single oral dose of Cytochrome P450 (CYP) substrates on Day 1. In Period 2, three IV doses of risankizumab on Days 1, 29 and 57, followed by single oral dose of CYP substrates on Day 64 will be administered.

    Drug: Risankizumab · Drug: Cytochrome P450 (CYP) Substrates

Interventions

  • Intravenous (IV) infusion

    Also known as: SKYRIZI, ABBV-066

  • DrugCytochrome P450 (CYP) Substrates

    Tablet: Oral; CYP Substrates: midazolam, caffeine, warfarin, vitamin K, omeprazole and metoprolol

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Midazolam

    Maximum observed plasma concentration (Cmax) of Midazolam

    Time frame: Up to 71 Days

  2. Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam

    Time to maximum plasma concentration (Tmax) of Midazolam

    Time frame: Up to 71 Days

  3. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Midazolam

    Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

    Time frame: Up to 71 Days

  4. AUC From Time 0 to Infinity (AUCinf) of Midazolam

    Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

    Time frame: Up to 71 Days

  5. Terminal Phase Elimination Rate Constant (β) of Midazolam

    Terminal phase elimination rate constant (β) for Midazolam

    Time frame: Up to 71 Days

  6. Terminal Phase Elimination Half-Life (t1/2) of Midazolam

    Terminal phase elimination half-life (t1/2) of Midazolam

    Time frame: Up to 71 Days

  7. Maximum Observed Plasma Concentration (Cmax) of Caffeine

    Maximum observed plasma concentration (Cmax) of Caffeine

    Time frame: Up to 71 Days

  8. Time to Maximum Observed Plasma Concentration (Tmax) of Caffeine

    Time to maximum plasma concentration (Tmax) of Caffeine

    Time frame: Up to 71 Days

  9. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Caffeine

    Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

    Time frame: Up to 71 Days

  10. AUC From Time 0 to Infinity (AUCinf) of Caffeine

    Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

    Time frame: Up to 71 Days

  11. Terminal Phase Elimination Rate Constant (β) of Caffeine

    Terminal phase elimination rate constant (β) for Caffeine

    Time frame: Up to 71 Days

  12. Terminal Phase Elimination Half-Life (t1/2) of Caffeine

    Terminal phase elimination half-life (t1/2) of Caffeine

    Time frame: Up to 71 Days

  13. Maximum Observed Plasma Concentration (Cmax) of Warfarin

    Maximum observed plasma concentration (Cmax) of Warfarin

    Time frame: Up to 71 Days

  14. Time to Maximum Observed Plasma Concentration (Tmax) of Warfarin

    Time to maximum plasma concentration (Tmax) of Warfarin

    Time frame: Up to 71 Days

  15. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Warfarin

    Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

    Time frame: Up to 71 Days

  16. AUC From Time 0 to Infinity (AUCinf) of Warfarin

    Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

    Time frame: Up to 71 Days

  17. Terminal Phase Elimination Rate Constant (β) of Warfarin

    Terminal phase elimination rate constant (β) for Warfarin

    Time frame: Up to 71 Days

  18. Terminal Phase Elimination Half-Life (t1/2) of Warfarin

    Terminal phase elimination half-life (t1/2) of Warfarin

    Time frame: Up to 71 Days

  19. Maximum Observed Plasma Concentration (Cmax) of Omeprazole

    Maximum observed plasma concentration (Cmax) of Omeprazole

    Time frame: Up to 71 Days

  20. Time to Maximum Observed Plasma Concentration (Tmax) of Omeprazole

    Time to maximum plasma concentration (Tmax) of Omeprazole

    Time frame: Up to 71 Days

  21. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Omeprazole

    Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

    Time frame: Up to 71 Days

  22. AUC From Time 0 to Infinity (AUCinf) of Omeprazole

    Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

    Time frame: Up to 71 Days

  23. Terminal Phase Elimination Rate Constant (β) of Omeprazole

    Terminal phase elimination rate constant (β) for Omeprazole

    Time frame: Up to 71 Days

  24. Terminal Phase Elimination Half-Life (t1/2) of Omeprazole

    Terminal phase elimination half-life (t1/2) of Omeprazole

    Time frame: Up to 71 Days

  25. Maximum Observed Plasma Concentration (Cmax) of Metoprolol

    Maximum observed plasma concentration (Cmax) of Metoprolol

    Time frame: Up to 71 Days

  26. Time to Maximum Observed Plasma Concentration (Tmax) of Metoprolol

    Time to maximum plasma concentration (Tmax) of Metoprolol

    Time frame: Up to 71 Days

  27. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Metoprolol

    Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

    Time frame: Up to 71 Days

  28. AUC From Time 0 to Infinity (AUCinf) of Metoprolol

    Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

    Time frame: Up to 71 Days

  29. Terminal Phase Elimination Rate Constant (β) of Metoprolol

    Terminal phase elimination rate constant (β) for Metoprolol

    Time frame: Up to 71 Days

  30. Terminal Phase Elimination Half-Life (t1/2) of Metoprolol

    Terminal phase elimination half-life (t1/2) of Metoprolol

    Time frame: Up to 71 Days

07

Study locations

6 sites
  • Southern California Res. Ctr. /ID# 216257
    Coronado, California 92118-1408, United States
  • University Clinical Research /ID# 216823
    DeLand, Florida 32720, United States
  • Atlantic Medical Research Group /ID# 227465
    Margate, Florida 33063-5737, United States
  • Clinical Trials of Texas, Inc /ID# 216277
    San Antonio, Texas 78229, United States
  • Charite Research Organisation GmbH /ID# 218646
    Berlin, 10117, Germany
  • The Chaim Sheba Medical Center /ID# 223959
    Ramat Gan, Tel-Aviv 5265601, Israel
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Oct 2022, 28 months.

Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 28 months is above that.

Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2020
First posted
Feb 5, 2020
StartActual
May 27, 2020
Primary completionActual
Oct 14, 2022
CompletionActual
Oct 14, 2022
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04254783
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
May 27, 2020
Primary completion
Oct 14, 2022
Completion
Oct 14, 2022
Last update
Jul 1, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion